NCT04516681
Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Minor Interventions: Adebrelimab (Drug), Ascorbic acid (Drug), FOLFOXIRI Protocol (Drug) to Adebrelimab (Drug), Ascorbic acid (Drug), FOLFOX Protocol (Drug)v3
- Notable Primary and study completion dates pushed to Dec 1, 2025
- Start date: Sep 1, 2020 to Dec 1, 2024
- Interventions: Ascorbic acid (Drug), FOLFOXIRI Protocol (Drug) to Adebrelimab (Drug), Ascorbic acid (Drug), FOLFOXIRI Protocol (Drug)
- Study title expanded, about 3 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Objective Response Rate
Timeframe: up to 5 years
Secondary (2)
Progression Free Survival
Overall Survival
Arms and interventions
Combined Ascorbic Acid with Adebrelimab and chemotherapy groupExperimental
Ascorbic Acid with Adebrelimab and FOLFOX ± bevacizumab. Ascorbic Acid (1.5g/kg/day, D1-3) every 2 weeks
Chemotherapy alone groupActive comparator
standard FOLFOX treatment
Drugs: Ascorbic acid, FOLFOX Protocol, Adebrelimab
Sites
1 site in 1 country
- Fudan university shanghai cancer centerShanhai, Shanghai Municipality, China